Skip to main content

Noema Pharma raises 103 million Swiss francs from investors

| News

Noema Pharma raises 103 million Swiss francs from investors

07.03.2023

Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round. The Basel-based biotech firm, which specializes in the area of debilitating diseases of the central nervous system, will use this fresh capital injection to advance its clinical-phase products.

Noema Pharma has successfully closed a Series B financing round. The biotech firm was able to raise gross proceeds in the amount of 103 million Swiss francs from both existing and new investors, further details of which can be found in a press release. The financing round was led by the European investment firms Forbion and Jeito Capital. Nanna Lüneborg from Forbion and Rachel Mears from Jeito Capital will now join the Board of Directors of Noema Pharma.

Noema Pharma specializes in debilitating diseases of the central nervous system. The proceeds from this financing round will be used to advance Noema’s clinical-stage product candidates. These include the lead product basimglurant for severe pain in trigeminal neuralgia and seizures related to tuberous sclerosis. Investigations into a drug for the treatment of Tourette’s syndrome and stuttering are also in progress.

Very encouraging clinical data

Nanna Lüneborg, General Partner at Forbion, believes this is the right time for an investment due to the fact that the company “has started to generate very encouraging clinical data in indications of high unmet need”. This applies in particular to the lead product basimglurant.

Noema Pharma was founded in 2019 following a seed investment from the Paris-based venture capital firm Sofinnova Partners and four clinical-stage products in-licensed by Roche. According to Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, the company is “incredibly proud” of everything that Noema Pharma has achieved since its inception. The current capital increase comes on the back of a Series A financing round closed in December 2020, in which the company raised a total of 54 million Swiss francs (converted from US dollars). This was also led by Sofinnova Partners together with Polaris Partners from the USA.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

biGENIUS receives 2 million euros for new cloud product

Software company biGENIUS, based in the Basel Area, has secured financing of 2 million euros. This funding was granted following...
Read More

Opterion Health secures investment of 6.5 million Swiss francs

Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which...
Read More

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Do you have a question? We'd like to hear from you.